These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 31151986)

  • 1. ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model.
    Chiang CL; Goswami S; Frissora FW; Xie Z; Yan PS; Bundschuh R; Walker LA; Huang X; Mani R; Mo XM; Baskar S; Rader C; Phelps MA; Marcucci G; Byrd JC; Lee LJ; Muthusamy N
    Blood; 2019 Aug; 134(5):432-444. PubMed ID: 31151986
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Rassenti LZ; Balatti V; Ghia EM; Palamarchuk A; Tomasello L; Fadda P; Pekarsky Y; Widhopf GF; Kipps TJ; Croce CM
    Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10731-10736. PubMed ID: 28923920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.
    Mani R; Mao Y; Frissora FW; Chiang CL; Wang J; Zhao Y; Wu Y; Yu B; Yan R; Mo X; Yu L; Flynn J; Jones J; Andritsos L; Baskar S; Rader C; Phelps MA; Chen CS; Lee RJ; Byrd JC; Lee LJ; Muthusamy N
    Leukemia; 2015 Feb; 29(2):346-55. PubMed ID: 24947019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-27b-3p suppresses cell proliferation through targeting receptor tyrosine kinase like orphan receptor 1 in gastric cancer.
    Tao J; Zhi X; Zhang X; Fu M; Huang H; Fan Y; Guan W; Zou C
    J Exp Clin Cancer Res; 2015 Nov; 34():139. PubMed ID: 26576539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models.
    Vaisitti T; Arruga F; Vitale N; Lee TT; Ko M; Chadburn A; Braggio E; Di Napoli A; Iannello A; Allan JN; Miller LL; Lannutti BJ; Furman RR; Jessen KA; Deaglio S
    Blood; 2021 Jun; 137(24):3365-3377. PubMed ID: 33512452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
    Widhopf GF; Cui B; Ghia EM; Chen L; Messer K; Shen Z; Briggs SP; Croce CM; Kipps TJ
    Proc Natl Acad Sci U S A; 2014 Jan; 111(2):793-8. PubMed ID: 24379361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia.
    Cui B; Ghia EM; Chen L; Rassenti LZ; DeBoever C; Widhopf GF; Yu J; Neuberg DS; Wierda WG; Rai KR; Kay NE; Brown JR; Jones JA; Gribben JG; Frazer KA; Kipps TJ
    Blood; 2016 Dec; 128(25):2931-2940. PubMed ID: 27815263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-34a and miR-29b as indicators for prognosis of treatment-free survival of chronic lymphocytic leukemia patients in Chinese Uygur and Han populations.
    Li Y; Mao M; Liu H; Wang X; Kou Z; Nie Y; Wang Y; Wang Z; Huang Q; Lang T; Gu Z; An L; Zhang X; Fu L
    Mol Cell Probes; 2019 Oct; 47():101436. PubMed ID: 31425738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.
    Huang X; Schwind S; Yu B; Santhanam R; Wang H; Hoellerbauer P; Mims A; Klisovic R; Walker AR; Chan KK; Blum W; Perrotti D; Byrd JC; Bloomfield CD; Caligiuri MA; Lee RJ; Garzon R; Muthusamy N; Lee LJ; Marcucci G
    Clin Cancer Res; 2013 May; 19(9):2355-67. PubMed ID: 23493348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target.
    Palacios F; Yan XJ; Ferrer G; Chen SS; Vergani S; Yang X; Gardner J; Barrientos JC; Rock P; Burack R; Kolitz JE; Allen SL; Kharas MG; Abdel-Wahab O; Rai KR; Chiorazzi N
    Leukemia; 2021 Apr; 35(4):1037-1052. PubMed ID: 33504942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
    Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
    Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptotic effect of berberine via Bcl-2, ROR1, and mir-21 in patients with B-chronic lymphocytic leukemia.
    Mohammadlou M; Abdollahi M; Hemati M; Baharlou R; Doulabi EM; Pashaei M; Ghahremanfard F; Faranoush M; Kokhaei P
    Phytother Res; 2021 Apr; 35(4):2025-2033. PubMed ID: 33174291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.
    Hudecek M; Schmitt TM; Baskar S; Lupo-Stanghellini MT; Nishida T; Yamamoto TN; Bleakley M; Turtle CJ; Chang WC; Greisman HA; Wood B; Maloney DG; Jensen MC; Rader C; Riddell SR
    Blood; 2010 Nov; 116(22):4532-41. PubMed ID: 20702778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noncoding RNA genes in cancer pathogenesis.
    Pekarsky Y; Croce CM
    Adv Biol Regul; 2019 Jan; 71():219-223. PubMed ID: 30611710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model.
    D'Abundo L; Callegari E; Bresin A; Chillemi A; Elamin BK; Guerriero P; Huang X; Saccenti E; Hussein EMAA; Casciano F; Secchiero P; Zauli G; Calin GA; Russo G; Lee LJ; Croce CM; Marcucci G; Sabbioni S; Malavasi F; Negrini M
    Oncogene; 2017 Nov; 36(47):6617-6626. PubMed ID: 28783166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia.
    Kasar S; Underbayev C; Yuan Y; Hanlon M; Aly S; Khan H; Chang V; Batish M; Gavrilova T; Badiane F; Degheidy H; Marti G; Raveche E
    Oncogene; 2014 Jun; 33(25):3307-15. PubMed ID: 23995789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia.
    Sampath D; Liu C; Vasan K; Sulda M; Puduvalli VK; Wierda WG; Keating MJ
    Blood; 2012 Feb; 119(5):1162-72. PubMed ID: 22096249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting malignant B cells with an immunotoxin against ROR1.
    Baskar S; Wiestner A; Wilson WH; Pastan I; Rader C
    MAbs; 2012; 4(3):349-61. PubMed ID: 22531447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How receptor tyrosine kinase-like orphan receptor 1 meets its partners in chronic lymphocytic leukemia.
    Mouawad N; Ruggeri E; Capasso G; Martinello L; Visentin A; Frezzato F; Trentin L
    Hematol Oncol; 2024 Mar; 42(2):e3250. PubMed ID: 38949887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.
    Baskar S; Kwong KY; Hofer T; Levy JM; Kennedy MG; Lee E; Staudt LM; Wilson WH; Wiestner A; Rader C
    Clin Cancer Res; 2008 Jan; 14(2):396-404. PubMed ID: 18223214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.